Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2020-02-19 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
首次公开发行股票科创板上市公告书
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市公告书" which translates to "Listing Announcement" or "IPO Listing Announcement" for Bio-Thera Solutions, Ltd. It contains detailed information about the company's initial public offering (IPO) on the Shanghai Stock Exchange's STAR Market (科创板), including stock code, issuance details, risk factors, shareholder structure, and regulatory approvals from the China Securities Regulatory Commission (CSRC) and Shanghai Stock Exchange. The document is not a financial report like an annual or quarterly report, nor is it a transcript, audit report, or management report. It is a formal announcement related to the company's stock listing event. This fits the category of a Capital/Financing Update (CAP) because it announces the company's initial public offering and listing on the stock exchange, which is a capital market event involving financing activities. The document length (15,000 characters) and detailed content confirm it is not a mere announcement of a report (RPA) but a substantive filing about the IPO listing.
2020-02-19 Chinese
公司章程
Governance Information Classification · 95% confidence The document is a detailed draft of the company's Articles of Association (章程草案) for 百奥泰生物制药股份有限公司, including comprehensive sections on company structure, shareholder rights, board and management, share issuance, shareholder meetings, and governance rules. It references the company's IPO and listing on the Shanghai Stock Exchange STAR Market (科创板). The document is a legal and governance framework document, not a financial report, earnings release, or announcement. It is not a proxy solicitation or voting results announcement, but rather the company's internal governance charter draft. This fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length (15,000 characters) and content confirm it is the actual governance document, not a brief announcement or summary. Therefore, the correct classification is CGR with high confidence.
2020-02-19 Chinese
首次公开发行股票并在科创板上市招股说明书.PDF
Capital/Financing Update Classification · 100% confidence The document is titled as a "首次公开发行股票并在科创板上市招股说明书" which translates to "Initial Public Offering (IPO) Prospectus for listing on the STAR Market." It contains detailed information about the company's business, products, risks, financial data, and the offering details such as number of shares, price, underwriting institutions, and regulatory disclosures. This is a comprehensive IPO prospectus document, which is a type of capital market filing related to the issuance of new shares and listing on a stock exchange. It is not an annual report, earnings release, or any other report type. It is clearly an offering document related to capital raising and listing. Therefore, the most appropriate classification is "Capital/Financing Update (CAP)" which covers updates on company fundraising, financing activities, or capital structure changes, including IPO prospectuses.
2020-02-16 Chinese
首次公开发行股票并在科创板上市发行结果公告
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行结果公告" which translates to "Issuance Results Announcement" for 百奥泰生物制药股份有限公司's initial public offering (IPO) and listing on the STAR Market (科创板). It details the results of the stock issuance, including the number of shares issued, pricing, allocation to strategic investors, online and offline subscription results, and the underwriting details. The document includes detailed subscription statistics, allotment results, and underwriting arrangements. It is a formal announcement of the results of a capital raising event (IPO). It is not a full financial report, audit report, or management discussion, nor is it a regulatory filing or proxy statement. It is specifically an update on the capital raising and issuance results. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is substantial and contains detailed data, not just a brief announcement or link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2020-02-16 Chinese
首次公开发行股票并在科创板上市网下初步配售结果及网上中签结果公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial public offering (IPO) of 百奥泰生物制药股份有限公司, including the offline preliminary allotment results and online lottery results for the stock issuance on the Shanghai Stock Exchange's STAR Market (科创板). It contains extensive information about the underwriting syndicate, strategic placement, offline and online subscription details, allotment results, subscription obligations, and related procedures. The document is not a financial report like an annual or interim report, nor is it a transcript, audit report, or management report. It is a formal announcement of the results of a capital raising event (IPO) and the allocation of shares to investors. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length is substantial and contains detailed data, not just a brief notice or a report publication announcement. Therefore, the appropriate classification is CAP with high confidence.
2020-02-12 Chinese
首次公开发行股票并在科创板上市网上发行申购情况及中签率公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the initial public offering (IPO) of 百奥泰生物制药股份有限公司, detailing the subscription situation, allocation results, and lottery for the online issuance of shares on the STAR Market (科创板). It includes information about the underwriting syndicate, subscription numbers, allocation ratios, and the lottery process for share allotment. The document does not contain financial statements or detailed financial analysis but rather provides procedural and subscription outcome information related to the IPO. It is not a full annual or interim report, earnings release, or management discussion. It is also not a proxy, voting result, or board change announcement. The document is a regulatory announcement about the IPO subscription and allocation results, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other more specific categories.
2020-02-11 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.